Dr. Schiller will discuss the limitations of currently available BPDCN treatments, the historical use of chemotherapy regimens and their potential to address unmet needs, and effective strategies for managing the financial burden and ensuring access to tagraxofusp for BPDCN patients.
Dr. Schiller will discuss the key factors that make the transplant ineligible BPDCN patient population more difficult to treat, the major goals of therapy for these patients, and how the mechanism of action of tagraxofusp suggests potential efficacy in BPDCN.
Dr. Schiller will discuss the key clinical and pathologic features that distinguish BPDCN from other malignancies, as well as the potential differential diagnoses that share a similar immunophenotype.
Discussing how various treatments for chronic GvHD impact quality of life in terms of disease response and side effects.
Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.
Rahul Banerjee, MD, discusses new frontiers in the treatment of multiple myeloma with CAR T-cell therapy.
Alex Chehrazi-Raffle, MD, discusses findings from a real-world analysis of adjuvant treatment in bladder cancer presented at ASCO GU.
This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
This segment focuses on the key considerations for diagnosing cGvHD and the initial treatment approaches, including the use of corticosteroids and combination therapies. The discussion covers factors that guide the decision-making process, such as organ involvement, severity of symptoms, and response to initial therapy.
Yara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.
Dr Shatsky provides clinical insights on treatment sequencing for patients undergoing treatment for HER2-positive breast cancer.
An expert on HER2+ breast cancer discusses exciting advancements in the treatment landscape, highlighting the DESTINY-Breast03 trial and trastuzumab deruxtecan.
Lova Sun, MD, MSCE, discusses targeted therapies for NTRK and RET alterations in thyroid cancers.
David L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.
Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.
Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.
Examining the efficacy and safety findings from recent studies on ibrutinib, ruxolitinib, and Belumosudil for chronic GvHD, and their implications for treatment choices.
Regina Barragan-Carrillo, MD, discusses an abstract which evaluated the association between thymectomy and incidence of renal cell carcinoma.
Rebecca A. Shatsky, MD, discusses the KATHERINE trial investigating adjuvant trastuzumab emtansine (T-DM1) in patients with residual invasive HER2+ breast cancer following neoadjuvant therapy.
Dr Shatsky discusses pertuzumab as a treatment for patients with HER2+ breast cancer, highlighting its mechanism of action as a HER2 dimerization inhibitor and updated data from the APHINITY trial.
Kim N. Chi, MD, FRCPC, discusses the significance of the phase 3 MAGNITUDE trial, including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer.
Dr. McCloskey discusses the limitations of current treatment options for BPDCN, as well as the emerging research and data that are most anticipated in the field.
Dr. McCloskey explores how various treatments for BPDCN impact the quality of life of patients, both in terms of disease response and side effects.
Dr. McCloskey discusses the general principles and practices for monitoring and mitigating adverse events, particularly capillary leak syndrome (CLS), in BPDCN patients treated with systemic agents like tagraxofusp.
Dr. McCloskey examines the potential of anti-CD123 CAR T-cell therapy for BPDCN, including the main challenges and limitations of this therapeutic approach.
Dr. McCloskey discusses the recent clinical trial results, such as the CADENZA trial, on the efficacy and safety of tagraxofusp in BPDCN patients.
Dr. McCloskey explores the mechanism of action and potential efficacy of tagraxofusp in the treatment of BPDCN.
Dr. McCloskey discusses the appropriateness of the initial therapy (tagraxofusp) based on NCCN guidelines, as well as the benefits and limitations of current treatment regimens for BPDCN.
Dr. McCloskey provides a brief overview of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including the clinical hallmarks of the disease and the challenges in recognizing and diagnosing this rare condition.
Lova Sun, MD, discusses the importance of identifying genetic alterations in thyroid cancer, including RET and NTRK alterations.